Modification of encephalomyocarditis virus-induced diabetes in mice by antiviral agents.
The current study used a murine model of diabetes induced by the D variant of encephalomyocarditis virus (DEMC) to determine the protective effect of exogenous antiviral agents. Antivirals, which were found to inhibit the development of DEMC virus cytopathic effect in L-929 cell monolayers, were administered intraperitoneally beginning 12 h prior to DEMC virus challenge. Arildone (500 mg/kg per day) or murine interferon (3.2 X 10(6) IU/kg per day) significantly reduced the incidence of hyperglycemia at 4 days after virus challenge. The incidences of hyperglycemia were 96% in untreated, 62% in arildone, and 0% in interferon treated mice. In other experiments we found that interferon (1.6 X 10(6) IU/kg per 12 h X 3) significantly protected mice against diabetes when administered at the time of virus infection or beginning 12 h afterwards. This effect was associated with reductions in average viral titers in the heart and pancreas of infected animals relative to untreated, infected mice. The results of these studies suggest that picornavirus induced diabetes may be prevented or ameliorated by the use of antiviral agents.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D003588:Cytopathogenic Effect, Viral; D003920:Diabetes Mellitus / Q000209:etiology / Q000517:prevention & control*; D004686:Encephalomyocarditis virus; D004769:Enterovirus Infections / Q000150:complications* / Q000188:drug therapy; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains
D000998:Antiviral Agents; D007372:Interferons